[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
November 2000

Intralesional Interferon Alfa for Treatment of Recurrent Lentigo Maligna of the Eyelid in a Patient With Primary Acquired Melanosis

Arch Dermatol. 2000;136(11):1415-1416. doi:

Primary acquired melanosis is characterized by hyperpigmented, macular lesions of the conjunctival epithelium.1 Many of these lesions may progress to melanoma, thus necessitating early diagnosis and management.2 Lentigo maligna refers to indolent melanoma in situ that occurs on sun-exposed areas of the head and neck.3 Treatment options have included excisional surgery, Mohs surgery, cryosurgery, and ruby laser surgery.410 Melanoma in situ of the eyelid represents a therapeutic challenge because of the need to balance tissue conservation with full clearance of the tumor and to reduce rates of recurrence and progression to invasive melanoma.11,12 We report the successful treatment of lentigo maligna of the eyelid in a patient with primary acquired melanosis using intralesional interferon alfa.

First Page Preview View Large
First page PDF preview
First page PDF preview
×